Information Provided By:
Fly News Breaks for April 26, 2017
BIIB
Apr 26, 2017 | 08:43 EDT
Leerink analyst Geoffrey Porges raised his price target for Biogen to $304 from $290 after the company reported better than expected Q1 results and a "strong" initial Spinraza launch. The analyst reiterates a Market Perform rating on the shares as he remains concerned about the outlook for Biogen's core Multiple sclerosis business, the paucity of catalysts or value in the company's pipeline.
News For BIIB From the Last 2 Days
BIIB
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.